Vera Therapeutics (VERA) Competitors $23.47 +1.13 (+5.06%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VERA vs. SRPT, BPMC, AXSM, NUVL, ADMA, KRYS, GRFS, CYTK, VRNA, and ELANShould you be buying Vera Therapeutics stock or one of its competitors? The main competitors of Vera Therapeutics include Sarepta Therapeutics (SRPT), Blueprint Medicines (BPMC), Axsome Therapeutics (AXSM), Nuvalent (NUVL), ADMA Biologics (ADMA), Krystal Biotech (KRYS), Grifols (GRFS), Cytokinetics (CYTK), Verona Pharma (VRNA), and Elanco Animal Health (ELAN). These companies are all part of the "pharmaceutical products" industry. Vera Therapeutics vs. Sarepta Therapeutics Blueprint Medicines Axsome Therapeutics Nuvalent ADMA Biologics Krystal Biotech Grifols Cytokinetics Verona Pharma Elanco Animal Health Sarepta Therapeutics (NASDAQ:SRPT) and Vera Therapeutics (NASDAQ:VERA) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, media sentiment, earnings, community ranking, analyst recommendations and dividends. Do analysts rate SRPT or VERA? Sarepta Therapeutics presently has a consensus target price of $158.70, indicating a potential upside of 156.96%. Vera Therapeutics has a consensus target price of $64.67, indicating a potential upside of 175.53%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Vera Therapeutics is more favorable than Sarepta Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sarepta Therapeutics 0 Sell rating(s) 5 Hold rating(s) 18 Buy rating(s) 1 Strong Buy rating(s) 2.83Vera Therapeutics 0 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 3 Strong Buy rating(s) 3.20 Do institutionals and insiders hold more shares of SRPT or VERA? 86.7% of Sarepta Therapeutics shares are owned by institutional investors. Comparatively, 99.2% of Vera Therapeutics shares are owned by institutional investors. 7.7% of Sarepta Therapeutics shares are owned by company insiders. Comparatively, 16.3% of Vera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Is SRPT or VERA more profitable? Sarepta Therapeutics has a net margin of 7.43% compared to Vera Therapeutics' net margin of 0.00%. Sarepta Therapeutics' return on equity of 11.00% beat Vera Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Sarepta Therapeutics7.43% 11.00% 3.35% Vera Therapeutics N/A -50.13%-39.50% Does the MarketBeat Community favor SRPT or VERA? Sarepta Therapeutics received 1431 more outperform votes than Vera Therapeutics when rated by MarketBeat users. Likewise, 75.03% of users gave Sarepta Therapeutics an outperform vote while only 66.13% of users gave Vera Therapeutics an outperform vote. CompanyUnderperformOutperformSarepta TherapeuticsOutperform Votes147275.03% Underperform Votes49024.97% Vera TherapeuticsOutperform Votes4166.13% Underperform Votes2133.87% Which has more risk & volatility, SRPT or VERA? Sarepta Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the S&P 500. Comparatively, Vera Therapeutics has a beta of 1.28, meaning that its stock price is 28% more volatile than the S&P 500. Does the media favor SRPT or VERA? In the previous week, Sarepta Therapeutics had 15 more articles in the media than Vera Therapeutics. MarketBeat recorded 22 mentions for Sarepta Therapeutics and 7 mentions for Vera Therapeutics. Vera Therapeutics' average media sentiment score of 1.49 beat Sarepta Therapeutics' score of 0.61 indicating that Vera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sarepta Therapeutics 8 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Positive Vera Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher valuation and earnings, SRPT or VERA? Vera Therapeutics has lower revenue, but higher earnings than Sarepta Therapeutics. Vera Therapeutics is trading at a lower price-to-earnings ratio than Sarepta Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSarepta Therapeutics$1.90B3.15-$535.98M$2.2827.09Vera TherapeuticsN/AN/A-$95.99M-$2.75-8.53 SummarySarepta Therapeutics beats Vera Therapeutics on 10 of the 18 factors compared between the two stocks. Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VERA vs. The Competition Export to ExcelMetricVera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.50B$6.59B$5.41B$7.70BDividend YieldN/A3.21%5.44%4.33%P/E Ratio-8.997.0522.1818.31Price / SalesN/A273.45397.31107.09Price / CashN/A65.6738.2034.62Price / Book12.106.506.834.25Net Income-$95.99M$142.50M$3.20B$247.51M7 Day Performance10.24%8.32%5.77%6.86%1 Month Performance-12.91%-5.61%-4.32%-2.95%1 Year Performance-39.34%0.11%17.88%5.17% Vera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VERAVera Therapeutics2.7766 of 5 stars$23.47+5.1%$64.67+175.5%-41.3%$1.50BN/A-8.9940Options VolumePositive NewsSRPTSarepta Therapeutics4.6705 of 5 stars$54.63+7.1%$161.83+196.2%-50.3%$5.30B$1.90B43.70840Positive NewsBPMCBlueprint Medicines2.6319 of 5 stars$82.53+2.1%$124.95+51.4%-6.7%$5.27B$508.82M-76.42640Upcoming EarningsNews CoverageAXSMAxsome Therapeutics4.5532 of 5 stars$103.53+5.6%$169.80+64.0%+48.1%$5.05B$385.69M-17.28380NUVLNuvalent1.8334 of 5 stars$70.00+5.6%$113.44+62.1%+10.1%$5.01BN/A-20.1740Positive NewsGap UpADMAADMA Biologics1.9 of 5 stars$20.91+7.8%$22.50+7.6%+245.7%$4.94B$426.45M74.68530News CoveragePositive NewsKRYSKrystal Biotech4.76 of 5 stars$168.91+2.4%$220.00+30.2%+6.3%$4.88B$290.52M56.49210News CoveragePositive NewsGRFSGrifols3.3415 of 5 stars$7.00+3.6%N/A+12.4%$4.81B$7.21B5.9826,300Gap UpCYTKCytokinetics4.0069 of 5 stars$39.81+3.0%$82.00+106.0%-39.6%$4.74B$18.47M-7.40250Analyst ForecastVRNAVerona Pharma2.1723 of 5 stars$57.81+0.2%$69.14+19.6%+325.1%$4.67B$42.28M-30.1130Analyst ForecastAnalyst RevisionNews CoveragePositive NewsGap UpELANElanco Animal Health3.9776 of 5 stars$8.69+0.8%$14.67+68.8%-29.0%$4.31B$4.44B21.739,800Analyst RevisionGap Up Related Companies and Tools Related Companies Sarepta Therapeutics Competitors Blueprint Medicines Competitors Axsome Therapeutics Competitors Nuvalent Competitors ADMA Biologics Competitors Krystal Biotech Competitors Grifols Competitors Cytokinetics Competitors Verona Pharma Competitors Elanco Animal Health Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VERA) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
